{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:14Z","timestamp":1790199554075,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to explore the relationship between laboratory indicators and short-term mortality risk in patients with thrombotic thrombocytopenic purpura (TTP) and to construct a risk stratification model. We retrospectively analyzed the clinical data of 106 patients with TTP admitted to Tongji Hospital between June 2016 and February 2025. Patients were grouped by 28-day survival: death (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200945) and survival (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200961). Prognosis-related indicators were identified using receiver operating characteristic (ROC) curves and logistic regression analyses. A mortality risk stratification model was established. To validate the stability of the model, 30 external cases of TTP (January 2022\u2013December 2024) were collected. The levels of cardiac troponin I (cTnI), lactate dehydrogenase (LDH), blood urea nitrogen (BUN), and indirect bilirubin (IBIL) were significantly higher in the death group compared to those in the survival group. ROC analysis identified optimal mortality risk cutoffs: cTnI at 353.1 pg\/mL (odds ratio [OR]\u2009=\u20094.778), LDH at 992 U\/L (OR\u2009=\u20092.842), BUN at 10.9 mmol\/L (OR\u2009=\u20095.527), and IBIL at 32.3 \u00b5mol\/L (OR\u2009=\u20092.995). A subsequent 0\u20134 point risk stratification model demonstrated increasing mortality rates of 21.3% (0\u20131 point), 39.1% (2 points), 60.9% (3 points), and 92.3% (4 points). Each 1-point increase in the risk score was associated with a 2.324-fold rise in mortality risk (95% confidence interval 1.597\u20133.383). Internal and external validations confirmed the model\u2019s stability and strong prognostic performance in patients with TTP. The risk model incorporating cTnI, LDH, BUN, and IBIL levels effectively predicted short-term mortality in patients with TTP. Patients with a score of 3 or higher required close monitoring and aggressive therapeutic intervention to mitigate mortality risk.\n                  <\/jats:p>","DOI":"10.1007\/s00277-025-06584-8","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T08:35:17Z","timestamp":1756542917000},"page":"4457-4464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura"],"prefix":"10.1007","volume":"104","author":[{"given":"Xu","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-qing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"4","key":"6584_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/jth.13956","volume":"16","author":"JA Kremer Hovinga","year":"2018","unstructured":"Kremer Hovinga JA, Heeb SR, Skowronska M et al (2018) Pathophysiology of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome[J]. J Thromb Haemost 16(4):618\u2013629","journal-title":"J Thromb Haemost"},{"issue":"11","key":"6584_CR2","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1007\/s00134-019-05736-5","volume":"45","author":"E Azoulay","year":"2019","unstructured":"Azoulay E, Bauer PR, Mariotte E et al (2019) Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura[J]. Intensive Care Med 45(11):1518\u20131539","journal-title":"Intensive Care Med"},{"issue":"5","key":"6584_CR3","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.21037\/apm-21-759","volume":"10","author":"Y Hao","year":"2021","unstructured":"Hao Y, Huang F, Jin J et al (2021) Clinical characteristics and outcomes of adult patients with acquired thrombotic thrombocytopenic purpura: a single center retrospective study[J]. Ann Palliat Med 10(5):5351\u20135358","journal-title":"Ann Palliat Med"},{"issue":"2","key":"6584_CR4","first-page":"176","volume":"22","author":"NG Mu\u00f1oz","year":"2024","unstructured":"Mu\u00f1oz NG, Ortega S, Solanich X et al (2024) Diagnosis and clinical management of thrombotic thrombocytopenic purpura (TTP): a consensus statement from the TTP Catalan group[J]. Blood Transfus 22(2):176\u2013184","journal-title":"Blood Transfus"},{"issue":"6","key":"6584_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","volume":"89","author":"CL Balduini","year":"2010","unstructured":"Balduini CL, Gugliotta L, Luppi M et al (2010) High versus standard dose Methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study. Ann Hematol 89(6):591\u2013596","journal-title":"Ann Hematol"},{"issue":"15","key":"6584_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/bloodadvances.2017008268","volume":"1","author":"JP Westwood","year":"2017","unstructured":"Westwood JP, Thomas M, Alwan F et al (2017) Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Adv 1(15):1159\u20131166","journal-title":"Blood Adv"},{"key":"6584_CR7","doi-asserted-by":"publisher","first-page":"103168","DOI":"10.1016\/j.eclinm.2025.103168","volume":"82","author":"P Coppo","year":"2025","unstructured":"Coppo P, Bubenheim M, Benhamou Y et al (2025) Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective cohort study (The Capla 1000\u2009+\u2009project). EClinicalMedicine 82:103168","journal-title":"EClinicalMedicine"},{"issue":"8","key":"6584_CR8","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/ajh.25845","volume":"95","author":"F Schieppati","year":"2020","unstructured":"Schieppati F, Russo L, Marchetti M et al (2020) Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study[J]. Am J Hematol 95(8):953\u2013959","journal-title":"Am J Hematol"},{"issue":"2","key":"6584_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jth.12790","volume":"13","author":"Y Benhamou","year":"2015","unstructured":"Benhamou Y, Boelle PY, Baudin B et al (2015) Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French thrombotic microangiopathies reference Center[J]. J Thromb Haemost 13(2):293\u2013302","journal-title":"J Thromb Haemost"},{"issue":"11","key":"6584_CR10","doi-asserted-by":"publisher","first-page":"1016e1","DOI":"10.1016\/j.amjmed.2013.03.021","volume":"126","author":"N Balasubramaniyam","year":"2013","unstructured":"Balasubramaniyam N, Kolte D, Palaniswamy C et al (2013) Predictors of in-hospital mortality and acute myocardial infarction in thrombotic thrombocytopenic purpura[J]. Am J Med 126(11):1016e1\u20131016e7","journal-title":"Am J Med"},{"issue":"8","key":"6584_CR11","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s00277-023-05248-9","volume":"102","author":"I Espa\u00f1ol","year":"2023","unstructured":"Espa\u00f1ol I, Leal JD, Blanquer M et al (2023) N-Acetylcistein for thrombotic thrombocytopenic purpura: an observational case series study[J]. Ann Hematol 102(8):2069\u20132075","journal-title":"Ann Hematol"},{"issue":"2","key":"6584_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/jca.21760","volume":"35","author":"N Zhao","year":"2020","unstructured":"Zhao N, Zhou L, Hu X et al (2020) A modified PLASMIC score including the lactate dehydrogenase\/the upper limit of normal ratio more accurately identifies Chinese thrombotic thrombocytopenic purpura patients than the original PLASMIC score[J]. J Clin Apher 35(2):79\u201385","journal-title":"J Clin Apher"},{"issue":"6","key":"6584_CR13","doi-asserted-by":"publisher","first-page":"e234091","DOI":"10.1136\/bcr-2019-234091","volume":"13","author":"S Goranta","year":"2020","unstructured":"Goranta S, Deliwala SS, Haykal T et al (2020) Severe primary refractory thrombotic thrombocytopenic purpura (TTP) in the post plasma exchange (PEX) and rituximab era[J]. BMJ Case Rep 13(6):e234091","journal-title":"BMJ Case Rep"},{"key":"6584_CR14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.thromres.2020.11.028","volume":"198","author":"ML Zhu","year":"2021","unstructured":"Zhu ML, Reeves HM, Maitta RW (2021) Immature platelet dynamics correlate with ADAMTS13 deficiency and predict therapy response in immune-mediated thrombotic thrombocytopenic purpura[J]. Thromb Res 198:72\u201378","journal-title":"Thromb Res"},{"issue":"2","key":"6584_CR15","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3324\/haematol.2011.051433","volume":"97","author":"R Froehlich-Zahnd","year":"2012","unstructured":"Froehlich-Zahnd R, George JN, Vesely SK et al (2012) Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura[J]. Haematologica 97(2):297\u2013303","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06584-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06584-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06584-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:33Z","timestamp":1761283833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06584-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6584"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06584-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has adhered to all pertinent national regulations and institutional policies, obtained approval from the local ethics committee, and received a waiver of informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval\u00a0<!--Emphasis Type='Bold' removed-->and informed consent"}},{"value":"All authors hereby confirm that the study is based on anonymized data and does not require consent. The manuscript does not contain any individual person\u2019s data in any form that can be used to identify the person, and all necessary steps have been taken to ensure the privacy and confidentiality of the participants\u2019 information. The authors declare that they have no competing interests and that the results presented in the study are honest and accurate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}